



Arbeitskreis Aids

Akademisches Lehrkrankenhaus

Infektiologischer Jahresrückblick 01.12.2021

1. Long MW, Snider DE, Jr., Farer LS: **U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.** *The American review of respiratory disease* 1979, **119**(6):879-894, DOI: 10.1164/arrd.1979.119.6.879.
2. Comstock GW, Baum C, Snider DE, Jr.: **Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies.** *The American review of respiratory disease* 1979, **119**(5):827-830, DOI: 10.1164/arrd.1979.119.5.827.
3. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A *et al*: **One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.** *N Engl J Med* 2019, **380**(11):1001-1011, DOI: 10.1056/NEJMoa1806808.
4. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ: **Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.** *N Engl J Med* 2014, **371**(17):1577-1587, DOI: 10.1056/NEJMoa1407426.
5. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J *et al*: **Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.** *N Engl J Med* 2021, **384**(18):1705-1718, DOI: 10.1056/NEJMoa2033400.
6. Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I *et al*: **A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.** *N Engl J Med* 2019, **380**(13):1201-1213, DOI: 10.1056/NEJMoa1811867.
7. Roelens M, Battista Migliori G, Rozanova L, Estill J, Campbell JR, Cegielski JP, Tiberi S, Palmero D, Fox GJ, Guglielmetti L *et al*: **Evidence-based Definition for Extensively Drug-resistant Tuberculosis.** *American journal of respiratory and critical care medicine* 2021, DOI: 10.1164/rccm.202009-3527OC.
8. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J *et al*: **Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.** *N Engl J Med* 2020, **382**(10):893-902, DOI: 10.1056/NEJMoa1901814.
9. Kong FY, Tabrizi SN, Fairley CK, Vodstrcil LA, Huston WM, Chen M, Bradshaw C, Hocking JS: **The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis.** *The Journal of antimicrobial chemotherapy* 2015, **70**(5):1290-1297, DOI: 10.1093/jac/dku574.



10. Dombrowski JC, Wierzbicki MR, Newman LM, Powell JA, Miller A, Dithmer D, Soge OO, Mayer KH: **Doxycycline Versus Azithromycin for the Treatment of Rectal Chlamydia in Men Who Have Sex With Men: A Randomized Controlled Trial.** *Clin Infect Dis* 2021, **73**(5):824-831, DOI: 10.1093/cid/ciab153.
11. Lau A, Kong FYS, Fairley CK, Templeton DJ, Amin J, Phillips S, Law M, Chen MY, Bradshaw CS, Donovan B *et al*: **Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis.** *N Engl J Med* 2021, **384**(25):2418-2427, DOI: 10.1056/NEJMoa2031631.
12. Blanco JL, Fuertes I, Bosch J, De Lazzari E, Gonzalez-Cordón A, Vergara A, Blanco-Arevalo A, Mayans J, Inciarte A, Estrach T *et al*: **Effective Treatment of Lymphogranuloma venereum Proctitis With Azithromycin.** *Clin Infect Dis* 2021, **73**(4):614-620, DOI: 10.1093/cid/ciab044.
13. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA: **Sexually Transmitted Infections Treatment Guidelines, 2021.** *MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports* 2021, **70**(4):1-187, DOI: 10.15585/mmwr.rr7004a1.
14. McKenney J, Bauman S, Neary B, Detels R, French A, Margolick J, Doherty B, Klausner JD: **Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.** *Clin Infect Dis* 2015, **60**(6):959-965, DOI: 10.1093/cid/ciu937.
15. Katchanov J, Jefferys L, Tominski D, Wostmann K, Slevogt H, Arasteh K, Stocker H: **Cryptococcosis in HIV-infected hospitalized patients in Germany: Evidence for routine antigen testing.** *J Infect* 2015, **71**(1):110-116, DOI: 10.1016/j.jinf.2015.01.011.
16. Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, Vitoria M, Doherty M, Meintjes G: **CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis.** *Clin Infect Dis* 2018, **66**(suppl_2):S152-s159, DOI: 10.1093/cid/cix1143.
17. Wake RM, Britz E, Sriruttan C, Rukasha I, Omar T, Spencer DC, Nel JS, Mashamaite S, Adelekan A, Chiller TM *et al*: **High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients.** *Clin Infect Dis* 2018, **66**(5):686-692, DOI: 10.1093/cid/cix872.
18. Longley N, Jarvis JN, Meintjes G, Boulle A, Cross A, Kelly N, Govender NP, Bekker LG, Wood R, Harrison TS: **Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.** *Clin Infect Dis* 2016, **62**(5):581-587, DOI: 10.1093/cid/civ936.



19. Govender NP, Meintjes G, Mangena P, Nel J, Potgieter S, Reddy D, Rabie H, Wilson D, Black J, Boulware D *et al*: **Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update.** *Southern African journal of HIV medicine* 2019, **20**(1):1030, DOI: 10.4102/sajhivmed.v20i1.1030.
20. Wake RM, Govender NP, Omar T, Nel C, Mazanderani AH, Karat AS, Ismail NA, Tiemessen CT, Jarvis JN, Harrison TS: **Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program.** *Clin Infect Dis* 2020, **70**(8):1683-1690, DOI: 10.1093/cid/ciz485.
21. Rajasingham R, Boulware DR: **Cryptococcal Antigen Screening and Preemptive Treatment-How Can We Improve Survival?** *Clin Infect Dis* 2020, **70**(8):1691-1694, DOI: 10.1093/cid/ciz488.
22. Bernard L, Arvieux C, Brunschweiler B, Touchais S, Ansart S, Bru JP, Oziol E, Boeri C, Gras G, Druon J *et al*: **Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection.** *N Engl J Med* 2021, **384**(21):1991-2001, DOI: 10.1056/NEJMoa2020198.
23. Drekonja DM, Trautner B, Amundson C, Kuskowski M, Johnson JR: **Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial.** *Jama* 2021, **326**(4):324-331, DOI: 10.1001/jama.2021.9899.
24. Dinh A, Ropers J, Duran C, Davido B, Deconinck L, Matt M, Senard O, Lagrange A, Makhloufi S, Mellon G *et al*: **Discontinuing β -lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.** *Lancet* 2021, **397**(10280):1195-1203, DOI: 10.1016/s0140-6736(21)00313-5.
25. Dinh A: **Antibiotic treatment duration for bacteraemic pneumonia - Author's reply.** *Lancet* 2021, **398**(10310):1485-1486, DOI: 10.1016/s0140-6736(21)01732-3.
26. Lee RA, Centor RM, Humphrey LL, Jokela JA, Andrews R, Qaseem A, Akl EA, Bledsoe TA, Forciea MA, Haeme R *et al*: **Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians.** *Ann Intern Med* 2021, **174**(6):822-827, DOI: 10.7326/m20-7355.
27. Stuart B, Hounkpatin H, Becque T, Yao G, Zhu S, Alonso-Coello P, Altiner A, Arroll B, Böhning D, Bostock J *et al*: **Delayed antibiotic prescribing for respiratory tract infections: individual patient data meta-analysis.** *Bmj* 2021, **373**:n808, DOI: 10.1136/bmj.n808.



28. Mora-López L, Ruiz-Edo N, Estrada-Ferrer O, Piñana-Campón ML, Labró-Ciurans M, Escuder-Perez J, Sales-Mallafré R, Rebasas-Cladera P, Navarro-Soto S, Serra-Aracil X: **Efficacy and Safety of Nonantibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study): A Multicentre, Randomised, Open-label, Noninferiority Trial.** *Annals of surgery* 2021, **274**(5):e435-e442, DOI: 10.1097/sla.0000000000005031.
29. Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, Bredeek F, García Deltoro M, Swindells S, Andrade-Villanueva JF *et al*: **Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.** *Lancet* 2021, **396**(10267):1994-2005, DOI: 10.1016/s0140-6736(20)32666-0.
30. Gray GE, Bekker LG, Laher F, Malahleha M, Allen M, Moodie Z, Grunenberg N, Huang Y, Grove D, Prigmore B *et al*: **Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.** *N Engl J Med* 2021, **384**(12):1089-1100, DOI: 10.1056/NEJMoa2031499.
31. Lockman S, Brummel SS, Ziembra L, Stranix-Chibanda L, McCarthy K, Coletti A, Jean-Philippe P, Johnston B, Krotje C, Fairlie L *et al*: **Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.** *Lancet* 2021, **397**(10281):1276-1292, DOI: 10.1016/s0140-6736(21)00314-7.
32. Murray MM, Lin J, Buros Stein A, Wilcox ML, Cottreau J, Postelnick M, Palella FJ: **Relationship of polypharmacy to HIV RNA suppression in people aged \geq 50 years living with HIV.** *HIV Med* 2021, **22**(8):742-749, DOI: 10.1111/hiv.13122.
33. Stanford KA, McNulty MC, Schmitt JR, Eller DS, Ridgway JP, Beavis KV, Pittrak DL: **Incorporating HIV Screening With COVID-19 Testing in an Urban Emergency Department During the Pandemic.** *JAMA Intern Med* 2021, DOI: 10.1001/jamainternmed.2021.0839.
34. Edwards JK, Cole SR, Breger TL, Rudolph JE, Filiatreau LM, Buchacz K, Humes E, Rebeiro PF, D'Souza G, Gill MJ *et al*: **Mortality Among Persons Entering HIV Care Compared With the General U.S. Population : An Observational Study.** *Ann Intern Med* 2021, **174**(9):1197-1206, DOI: 10.7326/m21-0065.
35. Marra F, Ruckenstein J, Richardson K: **A meta-analysis of stroke risk following herpes zoster infection.** *BMC Infect Dis* 2017, **17**(1):198, DOI: 10.1186/s12879-017-2278-z.



36. Yang Q, Chang A, Tong X, Merritt R: **Herpes Zoster Vaccine Live and Risk of Stroke Among Medicare Beneficiaries: A Population-Based Cohort Study.** *Stroke* 2021, **52**(5):1712-1721, DOI: 10.1161/strokeaha.120.032788.
37. Yang Q, George MG, Chang A, Tong X, Merritt R, Hong Y: **Effect of herpes zoster vaccine and antiviral treatment on risk of ischemic stroke.** *Neurology* 2020, **95**(6):e708-e717, DOI: 10.1212/wnl.0000000000010028.
38. Arens Y, Gaisa M, Goldstone SE, Liu Y, Wisnivesky J, Sigel CS, Swartz TH, Sigel K: **Risk of Invasive Anal Cancer in HIV-Infected Patients With High-Grade Anal Dysplasia: A Population-Based Cohort Study.** *Diseases of the colon and rectum* 2019, **62**(8):934-940, DOI: 10.1097/dcr.0000000000001384.
39. Revollo B, Videla S, Llibre JM, Paredes R, Piñol M, García-Cuyàs F, Ornelas A, Puig J, Parés D, Corral J *et al*: **Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study.** *Clin Infect Dis* 2020, **71**(2):390-399, DOI: 10.1093/cid/ciz831.
40. Glynn-Jones R, Sebag-Montefiore D, Meadows HM, Cunningham D, Begum R, Adab F, Benstead K, Harte RJ, Stewart J, Beare S *et al*: **Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.** *The Lancet Oncology* 2017, **18**(3):347-356, DOI: 10.1016/s1470-2045(17)30071-2.
41. Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, Benson A, Bryant A, Peckitt C, Segelov E *et al*: **International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2020, **38**(22):2510-2518, DOI: 10.1200/jco.19.03266.
42. Chammartin F, Lodi S, Logan R, Ryom L, Mocroft A, Kirk O, d'Arminio Monforte A, Reiss P, Phillips A, El-Sadr W *et al*: **Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study.** *Ann Intern Med* 2021, **174**(6):768-776, DOI: 10.7326/m20-5226.